Stay Ahead of the Curve
Breaking News in Lipid Nanoparticle (LNP) Delivery: Industry News & Reports
Keep pace with the latest breakthroughs in LNP delivery, strategic partnerships, and investment trends from BioXconomy—your trusted source for industry intelligence.
Partnerships & Collaborations
Discover how industry leaders are collaborating to advance lipid nanoparticles (LNPs) as non-viral delivery systems and therapeutics.
Corresponding author Sandra Chiu is a leading figure in Ebola science – but her career is colored by political intrigue.
The Democratic Republic of Congo (DRC) is actively dealing with one of the worst outbreaks of the Ebola virus since 2018, with over 1,000 suspected cases and more than 200 deaths. Despite decades of outbreaks in the DRC of the three most deadly strains in the orthoebolavirus family – Ebola, Sudan, and Bundibugyo virus – there are no vaccines available that protect against all three.
An article from our editorial partner, BioXconomy.
Millie Hoe, Reporter,BioProcess Insider
Manufacturing expert Telmo Graça believes a more agile CMC process will reduce costs and bring drugs to market faster.
The medical breakthroughs emerging from mRNA and lipid nanoparticle (LNP) research are astonishing. Whether it’s in vivo CRISPR treatments for rare disease or immunotherapy against cancer, these technologies are providing disease-modifying medicines that were previously unheard of.
An article from our editorial partner, BioXconomy.
Søren Hough, Editor, Drug Modalities, BioXconomy
Penn professor Kiran Musunuru is optimistic regulatory landscape can keep up with rapidly advancing genome editing technology.
Few moments in the history of medicine have been as earth-shaking as what scientists achieved in Philadelphia last year. For the first time, doctors delivered an mRNA-based CRISPR therapy directly to a human patient. The recipient was an infant named KJ born with a debilitating and potentially fatal metabolic disorder called carbamoyl-phosphate synthase 1 (CPS1) deficiency.
An article from our editorial partner, BioXconomy.
Søren Hough, Editor, Drug Modalities, BioXconomy.
Clinical-stage biotechnology firm CREATE Medicines has closed a $122 million Series B financing round to propel its pipeline forward.
Massachusetts-based CREATE Medicines has closed a $122 million Series B financing round, marking a significant milestone for the company as it advances its in vivo immune programming platform across autoimmune disease and oncology.
An article from our editorial partner, BioXconomy.
Millie Nelson, Senior Editor, Partnering and Investment, BioXconomy
Lipid nanoparticles have transformed the way biologics are delivered, creating robust and highly specific treatment options across a range of conditions.
From pancreatic cancer to reproductive disorders, lipid nanoparticles (LNPs) have proven to be an invaluable therapeutic tool. LNPs rose to prominence in the COVID-19 pandemic when they facilitated the delivery of millions of mRNA vaccines worldwide. That technology would go on to win the 2023 Nobel Prize in Physiology or Medicine, placing LNPs in the spotlight for mRNA researchers developing inoculations against HIV, RSV, and even brain parasites.
An article from our editorial partner, BioXconomy.
Millie Hoe, Reporter,BioProcess Insider
As delivery and design strategies improve, mRNA technology has ventured beyond vaccines to tackle some of the most pressing medical challenges of our time.
It was arguably a foregone conclusion when Katalin Karikó and Drew Weissman won the 2023 Nobel Prize in Physiology or Medicine for mRNA technology. Their decades of work underpinned one of the most important public health interventions of the modern era during the COVID-19 pandemic. Estimates suggest that vaccination against SARS-CoV-2 – including mRNA- and DNA-based inoculations – prevented 2.5 million deaths around the world.
An article from our editorial partner, BioXconomy.
Søren Hough, Editor, Drug Modalities, BioXconomy
mRNA delivered in vivo by antibody-targeted LNPs disrupts the defenses and microenvironment of pancreatic tumors.
Pancreatic cancer is a rare but devastating disease. Despite only accounting for around 3% of cancer cases in the US, it is responsible for 8% of all cancer deaths, with fewer than a fifth of patients expected to survive five years after their diagnosis.
An article from our editorial partner, BioXconomy.
Millie Hoe, Reporter,BioProcess Insider
Peptide-directed mRNA-LNP could treat reproductive disorders by thickening the uterine lining.
Over 176 million people worldwide suffer from endometriosis or endometrial disorders. Despite roughly 1 in 10 US women between the ages of 15–44 living with the condition, as well as other people with uteruses, it takes an average of over seven years to get diagnosed. Endometrial disorders can severely impact the likelihood of natural conception in later life; up to 30% of women with endometriosis experience fertility problems.
An article from our editorial partner, BioXconomy.
Millie Hoe, Reporter, BioProcess Insider
An innovative bispecific siRNA design hits two genes at once, taking away one of cancer’s tricks for evading treatment.
Some might say genetics research is in a rut. Biologists have made incredible biological and therapeutic discoveries over the past several decades, saving countless lives in the process. Yet many of these breakthroughs have relied on a simple formula: one gene, one disease.
An article from our editorial partner, BioXconomy.
Søren Hough, Editor, Drug Modalities, BioXconomy